Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

Share this content:
In this study, researchers assigned 39 heavily treated patients with R/R multiple myeloma to receive the PANEX protocol.
In this study, researchers assigned 39 heavily treated patients with R/R multiple myeloma to receive the PANEX protocol.

Panobinostat plus bortezomib and dexamethasone is tolerable and effective for relapsed/refractory (R/R) multiple myeloma in patients who had failed multiple lines of therapy, according to a study published in Clinical Lymphoma, Myeloma & Leukemia.

The phase 3 PANORAMA-1 trial demonstrated that the panobinostat plus bortezomib and dexamethasone regimen significantly prolonged progression-free survival (PFS) by 4 months, leading to US FDA approval for the treatment of patients with R/R multiple myeloma. However, some aspects of the study design were limited as PANORAMA-1 excluded patients who failed previous bortezomib therapy and only allowed for intravenous bortezomib administration, eliciting concerns about tolerability.

For this treatment-expansion study, researchers assigned 39 heavily treated patients with R/R multiple myeloma to receive the panobinostat, bortezomib, and dexamethasone (PANEX) protocol; PANEX was designed to provide access to panobinostat and additional data before commercial availability in the United States. In contrast with the PANORAMA-1 study, investigators were able to administer bortezomib subcutaneously, and patients who failed bortezomib previously were eligible.

Overall, 87% of patients received subcutaneous bortezomib. Results showed that of the 39 study participants, 22 achieved a partial response for an overall response rate (ORR) of 56%. Seven patients (18%) had a best response of minimal response, and 9 (23%) patients had a best response of no change. All patients in the study achieved a best response of stable disease or better.

The safety profile of PANEX was comparable to those previously reported. The most frequently reported grade 3 or 4 adverse events included thrombocytopenia, fatigue, dehydration, and diarrhea, and key all-grade adverse events associated with treatment included pneumonia, asthenia, vomiting, and peripheral neuropathy.

The authors concluded that “overall, data from the PANEX trial support regulatory approval of panobinostat plus bortezomib and dexamethasone and suggest the potential tolerability benefits of subcutaneous bortezomib in this regimen.”

Reference

Hansen VL, Coleman M, Elkins S, et al. An expanded treatment protocol of panobinostat plus bortezomib and dexamethasone in patients with previously treated myeloma[published online March 13, 2018]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2018.03.002

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs